ELVN Q2 2020 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-2.37

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$550,000

Balance Sheet

Total Assets

$111M

Total Liabilities

$5M

Stockholders' Equity

$106M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$10M	-$6M	-85.4%
Net Income	-$10M	-$5M	-89.1%